📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 15:40
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Choksi Asia Q1 PAT at ₹0.96 Cr; Revenue Declines 22.5% YoY to ₹9.22 Cr
Choksi Asia reported a contraction in its top-line for Q1 FY27, with revenue falling 22.5% YoY to ₹9.22 Cr. Despite the revenue drop, Net Profit (PAT) showed a sequential recovery, growing 28% from ₹0.75 Cr in Q4 FY26 to ₹0.96 Cr this quarter. Profitability was supported by a significant 25.3% YoY reduction in total expenses, primarily driven by lower stock-in-trade purchases. The company maintains a lean balance sheet with a debt-to-equity ratio of 0.05.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a notable decline in revenue but improved sequential profitability and cost management.
Why it mattersFor a micro-cap company (₹138 Cr market cap), consistent profitability is key. The sharp drop in revenue is a concern, but the reduction in expenses suggests flexible operational costs.
Revenue (Q1 FY27): ₹9.22 CrNet Profit (Q1 FY27): ₹0.96 CrYoY Revenue Growth: -22.5%QoQ PAT Growth: 27.8%Q1 Revenue vs TTM Revenue: 18.7%
📅 Short termThe stock may experience neutral to slightly negative sentiment due to the YoY revenue decline, though the sequential profit growth provides a floor.
📈 Long termThe company remains a small player in the medical equipment and testing space; long-term value depends on scaling revenue beyond the current ₹50 Cr annual range.
⚠ Risk flags
- Significant YoY revenue contraction
- Single segment concentration (Non-Destructive Testing)
- Small scale of operations
Key Highlights
Revenue from operations fell to ₹9.22 Cr in Q1 FY27 from ₹11.90 Cr in Q1 FY26.
Net Profit (PAT) stood at ₹0.96 Cr, down 10.3% YoY but up 28% sequentially.
Total expenses decreased to ₹7.97 Cr from ₹10.67 Cr in the year-ago period.
Earnings Per Share (EPS) for the quarter was ₹1.69 compared to ₹1.88 in the same quarter last year.
Profit Before Tax (PBT) margin improved to 16.7% compared to 12.7% in Q1 FY26.
👀 What to Watch
Investors should monitor the upcoming quarters to see if the revenue decline is a one-off cyclical event or a structural slowdown in the Non-Destructive Testing segment. The ability to maintain margins despite lower sales is a positive operational sign.
Choksi Asia Q1 FY27: Revenue Declines 22.5% YoY to ₹9.22 Cr; PAT Down 10.3%
Choksi Asia reported a weak start to FY27 with revenue from operations falling 22.5% YoY to ₹9.22 Cr. Net Profit followed suit, declining 10.3% YoY to ₹0.96 Cr, although it showed a sequential improvement of 27.8% from the previous quarter (₹0.75 Cr). The decline in revenue was partially offset by a sharp reduction in total expenses, which fell from ₹10.67 Cr to ₹7.97 Cr YoY, primarily due to lower stock-in-trade purchases. The company continues to operate exclusively in the Non-Destructive Testing industry segment.
Confidence: HIGH
What changedThe company experienced a significant contraction in business volume during Q1 FY27 compared to both the previous year and the previous quarter.
Why it mattersFor a small-cap company with a market cap of ₹138 Cr, a double-digit decline in revenue is material and may impact the premium valuation (P/E of 26.0) if growth does not recover quickly.
Revenue (Q1 FY27): ₹9.22 CrRevenue Growth (YoY): -22.5%Net Profit (Q1 FY27): ₹0.96 CrEPS (Q1 FY27): ₹1.69Revenue vs TTM Revenue: ~18.7%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the significant YoY decline in both top-line and bottom-line performance.
📈 Long termWhile FY26 showed strong annual growth, this quarter's performance raises concerns about sustainability; long-term outlook depends on the company's ability to scale its single-segment operations.
⚠ Risk flags
- Significant YoY revenue contraction
- Single-segment business concentration (Non-Destructive Testing)
- High valuation relative to current growth dip
Key Highlights
Revenue from operations fell to ₹9.22 Cr in Q1 FY27 from ₹11.90 Cr in Q1 FY26, a 22.5% drop.
Net Profit After Tax stood at ₹0.96 Cr, down 10.3% compared to ₹1.07 Cr in the year-ago period.
Total expenses decreased significantly to ₹7.97 Cr from ₹10.67 Cr YoY, driven by a reduction in stock-in-trade purchases to ₹1.96 Cr.
Earnings Per Share (EPS) for the quarter was ₹1.69, compared to ₹1.88 in Q1 FY26.
The company maintains a low debt profile with finance costs for the quarter at only ₹3.55 lakhs.
👀 What to Watch
Investors should monitor if the 22% revenue contraction is a cyclical trend in the Non-Destructive Testing industry or a company-specific loss of market share. The next quarter's results will be critical to determine if the company can return to the growth trajectory seen in FY26.
